Management to Make Two Presentations on the Topic of Drug Repurposing and
Indian Clinical Trial Strategy
MORRISTOWN, N.J., Aug. 16 /PRNewswire/ -- Vicus Therapeutics, Inc., an oncology-focused, clinical-stage biopharmaceutical company, announced today that Chief Executive Officer, John Maki, and Chief Scientific Officer, Frederic Young, Ph.D., will each present at the 234th American Chemical Society National Meeting on Sunday, August 19, 2007. The Meeting is being held at the Boston Convention & Exhibition Center in Boston, MA.
Dr. Young will present "Hypothesis-driven Drug Repurposing Based on a Novel Systems Biology Approach," including a discussion of Vicus' complexity theory-based drug repurposing approach in creating a pipeline of product candidates for the treatment of important unmet medical needs. The Company's approach can be applied to the discovery of product candidates for any indication, including cancer cachexia, a metabolic disorder, mucositis, a wound healing disorder, and cancer fatigue, a CNS disorder. The specific application of this method will be discussed in the context of the Company's lead compound, VT-122. Dr. Young's presentation is scheduled for 11:45 a.m.
Mr. Maki's presentation, entitled "Synergistic Advantages of Drug
Repurposing and Clinical Trial Off-shoring in India", will include a
discussion of the unique synergistic advantages of drug re-profiling and
off- shoring, as well as an overview of the steps necessary to realize such
advantages. Specifically, Mr. Maki will provide highlights from the
Company's ongoing Phase 2 clinical trial of VT-122 for cancer cachexia, now
being conducted in the U.S. and India. In addition, he will review recent
changes by the Drug Controller General of India (DCGI, the Indian
FDA-regulatory equivalent), Indian clinical research infrastructure, and
the acceptance of Indian data by the U.S. Food & Drug Administration (FDA)
that is currently driving the expl
|SOURCE Vicus Therapeutics|
Copyright©2007 PR Newswire.